Logo image of CDLX

CARDLYTICS INC (CDLX) Stock Fundamental Analysis

USA - NASDAQ:CDLX - US14161W1053 - Common Stock

1.88 USD
-0.12 (-6%)
Last: 10/17/2025, 8:00:44 PM
2.01 USD
+0.13 (+6.91%)
After Hours: 10/17/2025, 8:00:44 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CDLX. CDLX was compared to 95 industry peers in the Media industry. CDLX may be in some trouble as it scores bad on both profitability and health. CDLX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CDLX had negative earnings in the past year.
CDLX had a negative operating cash flow in the past year.
In the past 5 years CDLX always reported negative net income.
In the past 5 years CDLX always reported negative operating cash flow.
CDLX Yearly Net Income VS EBIT VS OCF VS FCFCDLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M

1.2 Ratios

CDLX's Return On Assets of -50.77% is on the low side compared to the rest of the industry. CDLX is outperformed by 84.04% of its industry peers.
CDLX has a Return On Equity of -312.30%. This is amonst the worse of the industry: CDLX underperforms 82.98% of its industry peers.
Industry RankSector Rank
ROA -50.77%
ROE -312.3%
ROIC N/A
ROA(3y)-46.33%
ROA(5y)-32.45%
ROE(3y)-196.76%
ROE(5y)-128.83%
ROIC(3y)N/A
ROIC(5y)N/A
CDLX Yearly ROA, ROE, ROICCDLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 54.73%, CDLX is in the better half of the industry, outperforming 64.89% of the companies in the same industry.
In the last couple of years the Gross Margin of CDLX has grown nicely.
CDLX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.66%
GM growth 5Y3.64%
CDLX Yearly Profit, Operating, Gross MarginsCDLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

CDLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDLX has been increased compared to 1 year ago.
The number of shares outstanding for CDLX has been increased compared to 5 years ago.
The debt/assets ratio for CDLX is higher compared to a year ago.
CDLX Yearly Shares OutstandingCDLX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CDLX Yearly Total Debt VS Total AssetsCDLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

CDLX has an Altman-Z score of -4.65. This is a bad value and indicates that CDLX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CDLX (-4.65) is worse than 82.98% of its industry peers.
A Debt/Equity ratio of 3.65 is on the high side and indicates that CDLX has dependencies on debt financing.
The Debt to Equity ratio of CDLX (3.65) is worse than 76.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.65
Debt/FCF N/A
Altman-Z -4.65
ROIC/WACCN/A
WACC5.06%
CDLX Yearly LT Debt VS Equity VS FCFCDLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CDLX has a Current Ratio of 1.16. This is a normal value and indicates that CDLX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CDLX (1.16) is comparable to the rest of the industry.
A Quick Ratio of 1.16 indicates that CDLX should not have too much problems paying its short term obligations.
CDLX has a Quick ratio of 1.16. This is comparable to the rest of the industry: CDLX outperforms 51.06% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
CDLX Yearly Current Assets VS Current LiabilitesCDLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

CDLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -444.44%.
Looking at the last year, CDLX shows a very negative growth in Revenue. The Revenue has decreased by -12.84% in the last year.
CDLX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.75% yearly.
EPS 1Y (TTM)-444.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y1.38%
Revenue growth 5Y5.75%
Sales Q2Q%-9.17%

3.2 Future

CDLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.68% yearly.
The Revenue is expected to grow by 6.30% on average over the next years.
EPS Next Y-34.69%
EPS Next 2Y6.93%
EPS Next 3Y28.68%
EPS Next 5YN/A
Revenue Next Year-10.85%
Revenue Next 2Y-7.58%
Revenue Next 3Y6.3%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CDLX Yearly Revenue VS EstimatesCDLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
CDLX Yearly EPS VS EstimatesCDLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDLX. In the last year negative earnings were reported.
Also next year CDLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDLX Price Earnings VS Forward Price EarningsCDLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDLX Per share dataCDLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as CDLX's earnings are expected to grow with 28.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.93%
EPS Next 3Y28.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDLYTICS INC

NASDAQ:CDLX (10/17/2025, 8:00:44 PM)

After market: 2.01 +0.13 (+6.91%)

1.88

-0.12 (-6%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners45.8%
Inst Owner Change0%
Ins Owners2.15%
Ins Owner Change9.65%
Market Cap100.09M
Analysts48
Price Target1.66 (-11.7%)
Short Float %12.39%
Short Ratio1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.51%
Min EPS beat(2)11.45%
Max EPS beat(2)21.57%
EPS beat(4)4
Avg EPS beat(4)43.06%
Min EPS beat(4)11.45%
Max EPS beat(4)100%
EPS beat(8)7
Avg EPS beat(8)48.47%
EPS beat(12)11
Avg EPS beat(12)44.2%
EPS beat(16)14
Avg EPS beat(16)39.48%
Revenue beat(2)1
Avg Revenue beat(2)0.68%
Min Revenue beat(2)-3.14%
Max Revenue beat(2)4.5%
Revenue beat(4)3
Avg Revenue beat(4)7.28%
Min Revenue beat(4)-3.14%
Max Revenue beat(4)14.02%
Revenue beat(8)3
Avg Revenue beat(8)0.82%
Revenue beat(12)4
Avg Revenue beat(12)0.47%
Revenue beat(16)7
Avg Revenue beat(16)1.47%
PT rev (1m)0%
PT rev (3m)-36.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-53.85%
EPS NY rev (1m)-35.53%
EPS NY rev (3m)-27.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.38
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS5
BVpS1.1
TBVpS-2.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.77%
ROE -312.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.73%
FCFM N/A
ROA(3y)-46.33%
ROA(5y)-32.45%
ROE(3y)-196.76%
ROE(5y)-128.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.66%
GM growth 5Y3.64%
F-Score3
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 3.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.23%
Cap/Sales 6.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z -4.65
F-Score3
WACC5.06%
ROIC/WACCN/A
Cap/Depr(3y)49.05%
Cap/Depr(5y)63.69%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-444.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y-34.69%
EPS Next 2Y6.93%
EPS Next 3Y28.68%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y1.38%
Revenue growth 5Y5.75%
Sales Q2Q%-9.17%
Revenue Next Year-10.85%
Revenue Next 2Y-7.58%
Revenue Next 3Y6.3%
Revenue Next 5YN/A
EBIT growth 1Y32.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.61%
EBIT Next 3Y42.15%
EBIT Next 5YN/A
FCF growth 1Y55.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.49%
OCF growth 3YN/A
OCF growth 5YN/A